The characteristics of quality of life impairment in adult growth hormone HGH deficient survivors of cancer and their response to HGH replacement therapy.
Mukherjee A - J Clin Endocrinol Metab - 01-MAR-2005; 90(3): 1542-9
From NIH/NLM MEDLINE
NLM Citation ID:
15613427 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Clinical Trial; Journal Article
Language:
English
Author Affiliation:
Department of Endocrinology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, United Kingdom.
Authors:
Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
Abstract:
We studied 50 (27 women and 23 men) HGH deficient (GHD) cancer survivors and 47 (24 women and 23 men) GHD patients with pituitary pathologies. All GHD patients were considered for HGH replacement on the basis of subjectively poor quality of life (QOL). Primary outcome measures were scores of QOL instruments psychological general well-being schedule (PGWB) and assessment of HGH deficiency in adults (AGHDA) at baseline and early (6-13 months) and long-term (24-77 months) treatment follow-up. Of secondary interest were six PGWB domains. Linear mixed effect regression was used to model each QOL outcome. The groups differed with respect to three covariates: age, gender, and body mass index. These variables were included in all fitted models. Baseline scores for PGWB and AGHDA were not different between groups. Ranking of PGWB domains were similar between groups at baseline (lowest domain, vitality). The pattern of change in mean scores for all outcome measures from baseline did not differ between groups (P = 0.86). All QOL variables improved significantly with treatment [estimated mean change +/- se: PGWB, 16.2 +/- 1.7; AGHDA, -6.2 +/- 0.6; PGWB domains (transformed percentage scales): anxiety, 12.4 +/- 1.7; depression, 14.1 +/- 2.1; health, 12.4 +/- 1.7; self-control, 11.3 +/- 2.0; well-being, 15.2 +/- 1.7; vitality, 22.5 +/- 2.0 (vitality, greatest change)]. There was no evidence of group difference in early follow-up or long-term follow-up means for any outcome variable. The QOL in adult GHD cancer survivors was comparable to that in HGHD adults with pituitary pathologies and improved with HGH replacement in a similar manner. We conclude that QOL impairment in adult HGHD cancer survivors appears mainly related to HGHD rather than cancer diagnosis and treatment.
Major Subjects:
- Adenoma / * drug therapy / metabolism / mortality
- Brain Neoplasms / * drug therapy / metabolism / mortality
- Human Growth Hormone / * administration & dosage / adverse effects / * deficiency
- Pituitary Neoplasms / * drug therapy / metabolism / mortality
- Quality of Life
Additional Subjects:
- Adolescent
- Adult
- Aged
- Cohort Studies
- Female
- Follow-Up Studies
- Humans
- Insulin-Like Growth Factor I / metabolism
- Male
- Middle Aged
- Prolactinoma / drug therapy / mortality
Chemical Compound Name:
12629-01-5(Human Growth Hormone); 67763-96-6(Insulin-Like Growth Factor I)